Wimbledon Health Partners is not only leading the diagnostic testing space, they are disrupting the industry. Physicians nationwide are seeing the benefit of on-site diagnostic testing, both to their practice and to their patients.
Boca Raton, Florida (PRWEB) June 24, 2014
In yet another sign of the company's continuing growth and market leadership, Wimbledon Health Partners (WHP), a leading on-site diagnostic testing company, appointed Karl Foust as Chief Financial Officer. Charged with managing the growing organizations financials and investor relations, Foust has a vast background in Fortune 500 companies. During his 29 years of experience in multiple industries Mr. Foust has led all aspects of financial and investment management to secure the highest financial return on capital; and analyzing, negotiating and integrating new business opportunities.
Hiring Mr. Foust further demonstrates Wimbledon Health Partners commitment to enhancing the strength of its senior management team, as well as the company overall. His expertise and ongoing role will include control treasury planning and analysis, investor relations, and human resource functions. This will help Wimbledon Health Partners enhance its financial operations to accommodate the company's continued growth, which is being fueled by the escalating need for the company's proven on-site diagnostic testing services.
“Wimbledon Health Partners is not only leading the diagnostic testing space, they are disrupting the industry. Physicians nationwide are seeing the benefit of on-site diagnostic testing, both to their practice and to their patients. Having adopted a model that engages physicians and supports patients through health education, a first of its kind. I came to Wimbledon because their business model is exceptional and the company is poised for tremendous growth in the months and years to come,” stated Foust.
About Wimbledon Health Partners:
Wimbledon Health Partners is a national on-site diagnostic testing organization with capabilities for diagnosing circulatory conditions that can be detected through the use of cardiovascular ultrasound. Additional capabilities include nerve conduction velocity testing (NCV), which is utilized to support the diagnosis of nerve involvement of circulatory disease, and help assess cardiovascular risk. Wimbledon Health Partners is an innovative cooperative marketing and practice-enhancement program that provides physicians with the educational, compliance, and marketing tools necessary to provide quality and state-of-the-art in-office testing procedures. For more information go to http://www.dxtesting.com or call 855-200-8262.